C
ITCI

Covestor’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Covestor’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,233
Closed -$163K – 2870
2025
Q1 		$163K Sell
1,233
-866
-41% -$108K 0.11% 221
2024
Q4 		$175K Buy
2,099
+288
+16% +$23.7K 0.11% 234
2024
Q3 		$133K Buy
1,811
+521
+40% +$39.2K 0.08% 366
2024
Q2 		$88K Sell
1,290
-1,354
-51% -$93.9K 0.06% 578
2024
Q1 		$183K Sell
2,644
-184
-7% -$12.6K 0.12% 196
2023
Q4 		$203K Buy
2,828
+310
+12% +$17.8K 0.14% 136
2023
Q3 		$131K Buy
2,518
+991
+65% +$57.7K 0.1% 284
2023
Q2 		$97K Sell
1,527
-906
-37% -$56.5K 0.07% 465
2023
Q1 		$132K Buy
2,433
+336
+16% +$16.2K 0.12% 249
2022
Q4 		$111K Buy
2,097
+209
+11% +$10.5K 0.09% 338
2022
Q3 		$88K Buy
1,888
+1,699
+899% +$88.8K 0.08% 422
2022
Q2 		$11K Buy
189
+177
+1,475% +$10K 0.01% 1197
2022
Q1 		$1K Sell
12
-3
-20% -$156 ﹤0.01% 2007
2021
Q4 		$1K Buy
+15
New +$630 ﹤0.01% 2014

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Covestor's ITCI Position: Q2 2025 in Review

Covestor sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,233 shares — an estimated $163K sold.

Covestor first reported a position in ITCI in Q4 2021 and held it in 14 quarters. The position peaked at $203K in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Covestor reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Covestor sold 1,233 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $163K.
  • Covestor first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 14 quarters.
  • Covestor's Intra-Cellular Therapies Inc. position peaked at $203K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Covestor's 13F filing for Q2 2025, filed 11 Aug 2025.